Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Remdesivir is a nucleotide analog prodrug with broad-spectrum antiviral activity, approved for the treatment of COVID-19 caused by SARS-CoV-2 in hospitalized and non-hospitalized patients. It functions by inhibiting the RNA-dependent RNA polymerase (RdRp), thereby interfering with viral RNA replication. Initially developed for Ebola virus, remdesivir has been repurposed and studied extensively in the treatment of COVID-19 and is the first antiviral to receive full FDA approval for this indication in the United States. Clinical trials have shown it can reduce time to recovery in hospitalized patients with moderate to severe disease.
Fact Table | |
Formula | C27H35N6O8P |
License | US FDA (2020) |
Bioavailability | Not applicable (IV only) |
Legal status | Prescription only |
Chemical Name | Remdesivir |
Elimination half-life | ~1 hour (parent); ~25 hours (active metabolite GS-441524) |
Dosage (Strength) | 100 mg lyophilized powder or solution for IV infusion |
Pregnancy | Use only if clearly needed; limited human data |
Brands | Veklury |
Protein binding | ~88–93% |
PubChem CID | 121304016 |
MedlinePlus | a620046 |
ChEBI | CHEBI:145994 |
ATC code | J05AB16 |
DrugBank | DB14761 |
KEGG | D11874 |
Routes of administration | Intravenous (IV infusion) |
Remdesivir is administered by intravenous infusion under medical supervision. The standard adult dosing for COVID-19 is:
Loading dose: 200 mg on Day 1
Maintenance dose: 100 mg once daily on Days 2–5 (up to 10 days in severe cases)
Each dose should be infused over 30 to 120 minutes, depending on the formulation. Dosing adjustments may be required for renal or hepatic impairment. It is not recommended in patients with eGFR <30 mL/min, unless benefits outweigh risks. Remdesivir should be initiated as early as possible in the disease course, ideally within 7 days of symptom onset.
Remdesivir is supplied as:
Lyophilized powder (100 mg/vial) or solution (100 mg/20 mL vial) for IV infusion
Each vial contains:
Remdesivir 100 mg
Inactive ingredients include:
Betadex sulfobutyl ether sodium (SBECD) as a solubilizing agent
Water for injection and pH adjusters (depending on formulation)
Remdesivir is contraindicated in patients with:
Known hypersensitivity to remdesivir or any excipients
Severe renal impairment (eGFR <30 mL/min) due to accumulation of SBECD, unless clinically justified
Monitor liver function during treatment, as transaminase elevations and rare cases of hepatotoxicity have been reported. Use with caution in patients with pre-existing liver disease. Monitor renal function, especially in patients with borderline renal function. Discontinue if ALT levels rise to >10× ULN or if accompanied by signs of liver inflammation. The safety of use in pregnant or breastfeeding women has not been fully established; use only if the potential benefit outweighs risk. Remdesivir should not be co-administered with chloroquine or hydroxychloroquine due to antagonistic effects on antiviral activity.
Common and potential side effects include:
Nausea
Elevated ALT and AST
Headache
Hypersensitivity or infusion-related reactions (fever, hypotension, chills)
Rare: renal toxicity, bradycardia, or rash